# Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever Compared A 51,540-person cohort links tirzepatide to less incident open-angle glaucoma than other GLP-1 drugs (HR 0.65, 95% CI 0.44-0.96) | and why a two-drug comparison has limits. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-glaucoma Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever Compared A 51,540-person comparison found less open-angle glaucoma on tirzepatide than on other GLP-1 drugs. Both arms were treated. Neither figure says what either drug does against taking nothing. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Tirzepatide vs other GLP-1 drugs · open-angle glaucoma, 2 years, age 60+ · no difference · 0.65 · 0.44 · 0.96 · Both arms are on a drug. Neither is compared with none. · 51,540 matched participants across 21 countries. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Among 51,540 matched adults aged 60 and over with type 2 diabetes across 21 countries, tirzepatide was associated with less incident open-angle glaucoma than other GLP-1 drugs over two years. - The hazard ratio was 0.65, with a 95% confidence interval of 0.44 to 0.96 — excluding 1, but only just. - Both arms were taking a drug in this class. The study has no untreated comparison, so it cannot say whether either raises or lowers glaucoma risk in absolute terms. - The result held across several sensitivity analyses, including an intention-to-treat design. No study has compared a GLP-1 user against an untreated person for glaucoma. The one large comparison that exists ranks two of these drugs against each other. It covered 51,540 matched adults aged 60 and over. Incident open-angle glaucoma came in at a hazard ratio of 0.65 (95% CI 0.44 to 0.96) on tirzepatide against other GLP-1 drugs [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma#ref-1). Eye safety has followed this class since the first reports of optic nerve damage, examined here in [the optic nerve evidence by indication](https://thisglp.com/research/semaglutide-optic-nerve-by-indication). The cohort covered adults aged 60 and over with type 2 diabetes, newly prescribed tirzepatide or another GLP-1 drug between 2022 and 2024. Matching was one to one on age, sex, race, smoking history, HbA1c, BMI, prior glucose-lowering medication, corticosteroid use and comorbidities. Anyone with existing glaucoma or prior glaucoma medication was excluded, as was anyone using both drug types during follow-up. Follow-up ran two years, and the result survived several sensitivity analyses including an intention-to-treat design. The separate optic nerve literature runs the other way and should not be folded in. Pooling eight cohorts, semaglutide carried a relative effect of 1.93 for non-arteritic anterior ischemic optic neuropathy (95% CI 1.22 to 3.08) [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma#ref-2). That is a different structure, a different nerve and a different comparison. Glaucoma is not NAION. Nobody in this study was untreated Both arms were on a drug from the same class. That makes this a ranking, not a risk assessment: it can tell you which of two treated groups had fewer glaucoma diagnoses, and it cannot tell you whether taking either one leaves you better or worse off than taking neither. A reader who comes away thinking tirzepatide protects the eyes has drawn a conclusion the design cannot reach. The interval is worth reading rather than rounding. An upper bound of 0.96 clears 1 by four hundredths. That makes the result real by the usual convention and fragile under any reasonable amount of unmeasured confounding. Two years is also a short window for a disease that develops over decades. And a diagnosis of open-angle glaucoma depends on somebody having an eye examination at all, which is the same detection problem that shapes [the retinopathy evidence](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse). What would make this more than a curiosity is a mechanism, and the study supplies none. Intraocular pressure, blood sugar variability and weight change are all plausible routes. None was measured. Until an untreated comparison exists, the practical use of this finding is narrow. It is one more small difference between two drugs usually discussed as interchangeable, alongside [the carpal tunnel comparison](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome) and [the network comparison](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). ## Frequently asked Does tirzepatide protect against glaucoma? The study cannot show that. Both groups were taking a GLP-1-class drug, so it compares two treatments with each other and has no untreated arm to measure absolute risk against. How strong is the result? The hazard ratio was 0.65 with a confidence interval of 0.44 to 0.96. It excludes 1 by a small margin, which makes it statistically significant by convention and sensitive to unmeasured confounding. Does this apply to younger people? It has not been shown to. The cohort was restricted to adults aged 60 and over, followed for two years, and measured only primary open-angle glaucoma. ## Sources 1. \[1\] Pan SY, Weng CH, Sheen YJ, Chen JP, et al. (2026). Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study Ophthalmology Science. [PMID 42383218](https://pubmed.ncbi.nlm.nih.gov/42383218/) 2. \[2\] Khani E, et al. (2026). Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis The Journal of Clinical Pharmacology. [PMID 42612051](https://pubmed.ncbi.nlm.nih.gov/42612051/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness)